Novartis Just Dropped $1.1B on a Company With Zero Clinical Data
Novartis dropped $1.1 billion upfront on a UK biotech with zero human data, marking its boldest entry into the red-hot ADC space. The bet: a completely novel payload class that could leapfrog every antibody-drug conjugate on the market today.
Every big pharma company wants to be in the antibody-drug conjugate game right now. Novartis just bought its entry ticket, and it wasn't cheap.
The Swiss giant agreed to acquire Myricx Bio, a small UK biotech, for $1.1 billion in cash upfront. There's another $400 million in milestone payments on the table, bringing the total potential price tag to $1.5 billion. The kicker? Myricx has never tested its technology in a single human being.
This is one of the richest upfront payments ever made for an early-stage ADC payload platform. And it tells you everything about how desperate Big Pharma is to win the ADC arms race.
What Novartis Actually Bought
To understand this deal, you need to understand what ADCs are and why pharma can't stop throwing money at them.
Antibody-drug conjugates are basically guided missiles for cancer. You take an antibody (the GPS system that finds tumor cells), attach a toxic payload (the warhead), and connect them with a chemical linker (the fuse). The antibody locks onto cancer cells, gets swallowed inside, and then the payload detonates, killing the cell from within.
The concept is elegant. The problem is that most ADCs today use one of two payload types: microtubule inhibitors or topoisomerase-1 (topo-1) inhibitors. Think of it like every restaurant in town serving either chicken or fish. Eventually, some tumors develop resistance to both. Doctors need a third option on the menu.
That's what Myricx brings. Its payloads work through N-myristoyltransferase inhibition, or NMTi for short. NMT is an enzyme that attaches fatty acids to certain proteins inside cells. Many of those proteins are essential for cancer cell survival. Block NMT, and you pull the rug out from under multiple survival pathways at once.
It's a completely different mechanism from anything on the market. In preclinical studies (animal models, not humans), Myricx's NMTi-based ADCs caused complete tumor regression in models that didn't respond to topo-1 ADCs. That's the kind of data that makes pharma executives reach for their checkbooks.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
The Senescence Trick
Myricx's platform has another party trick that caught Novartis' attention, and it involves zombie cells.
When cancer treatments damage tumor cells without fully killing them, those cells can enter a state called senescence: they stop dividing but refuse to die. Think of them as wounded soldiers who hunker down and start signaling for reinforcements. These senescent cells pump out inflammatory molecules that can actually help remaining cancer cells survive and spread.
Most ADC payloads can't touch senescent cells because they target actively dividing cells. Myricx's NMTi payloads are different. Senescent cells depend on a hyperactive secretory system (that signaling apparatus calling for reinforcements), and NMT is essential for making that system work. Block NMT, and senescent cells lose their lifeline too.
So you get a dual mechanism: kill the proliferating cancer cells and clear out the zombie cells that help tumors bounce back. It's like hiring an exterminator who also patches the holes where the bugs get in.
Why $1.1 Billion for Preclinical Data?
Let's be blunt: paying over a billion dollars upfront for a company with no human data is aggressive. Even by today's inflated ADC deal standards.
But context matters. The ADC space generated 913 transactions worth $368 billion between 2021 and 2025. Deal sizes have been climbing fast; the average roughly doubled from about $740 million in 2024 to $1.5 billion by mid-2025. Pharma is concentrating its capital on fewer, bigger bets.
Compare the Myricx deal to recent benchmarks. Gilead paid $3.15 billion upfront for Tubulis, a clinical-stage ADC platform company. Bristol Myers Squibb put down $1.5 billion upfront for BioNTech's bispecific antibody, BNT327. Taiho (an Otsuka subsidiary) paid $400 million upfront for Araris Biotech's linker-conjugation platform.
Myricx slots right into the top tier. The $1.1 billion upfront represents about 73% of the total deal value, which signals high conviction from Novartis. When a buyer front-loads the payment like that, it means they're not hedging; they believe in the science.
Also worth noting: Myricx raised roughly $115 million in its Series A back in 2024, led by Novo Holdings and Abingworth, with Eli Lilly participating. That means early investors just saw a roughly 10x step-up in value in about two years. Not a bad return for betting on an enzyme most people have never heard of.
Novartis Is Late to the Party (and Knows It)
This acquisition marks Novartis' formal entry into oncology ADCs, and the timing is telling. The company has watched from the sidelines as rivals spent tens of billions building ADC empires.
Pfizer set the standard in 2023 with its $43 billion acquisition of Seagen, the largest ADC deal in history. That gave Pfizer commercial ADCs (Adcetris, Padcev) plus a deep technology platform. AstraZeneca and Daiichi Sankyo have been co-developing their DXd payload platform for years, producing Enhertu, one of the most successful cancer drugs of the past decade. AbbVie grabbed ImmunoGen for $10.1 billion. Merck locked in a $22 billion partnership with Daiichi Sankyo for three ADCs.
Novartis was conspicuously absent from all of this. The company focused instead on radioligand therapies (a different type of targeted cancer treatment) and, more recently, on RNA conjugates through its $12 billion acquisition of Avidity Biosciences in late 2025.
Now, with Myricx, Novartis is making a deliberate choice. Rather than competing head-to-head in the crowded topo-1 payload space where AstraZeneca and Daiichi Sankyo dominate, it's betting on a next-generation payload class that could leapfrog the current generation entirely. It's the biotech equivalent of skipping 4G and going straight to 5G.
The Risks Are Real
Analysts and industry watchers are calling the deal "bold but rational." That's polite code for "we like the logic but there's a lot that could go wrong."
The biggest risk is obvious: no human data exists. Mouse models are promising, but oncology history is littered with preclinical superstars that flopped in patients. The human body has a way of humbling even the most elegant science. NMT inhibition could turn out to have unexpected toxicities, a narrower therapeutic window than hoped, or simply not work as well when the complexity of human biology enters the picture.
There's also integration risk. Myricx is a small, nimble startup. Novartis is a large multinational. Absorbing a tiny team's culture and speed into a bureaucratic giant doesn't always go smoothly. Novartis' oncology track record is strong, but every big pharma acquisition comes with execution risk.
Financially, the deal is manageable for a company of Novartis' size. Early sell-side commentary leans toward "strategically positive, financially contained." The near-term earnings impact is minimal, and the $1.1 billion, while substantial, doesn't move the needle on Novartis' balance sheet. Shares dipped about 2.2% around the announcement, though that was attributed more to broader market movement than deal backlash.
The Bigger Picture: Pharma's Payload Problem
Zoom out, and the Myricx deal illuminates a shift happening across the entire ADC industry.
For years, the competition centered on targets: who could find the best surface protein to aim their ADC at. HER2, TROP-2, B7-H3, and others became crowded battlegrounds. But the target side of the equation is running out of low-hanging fruit.
Now, the focus is shifting to payloads and platforms. The question isn't just "what are you aiming at?" It's "what bomb are you carrying?" Novel payload chemistry, like Myricx's NMTi class, offers something targets alone can't: a way to overcome resistance to existing treatments and potentially expand ADCs into tumor types where current options fall short.
Novartis executives have drawn an explicit parallel to their radioligand therapy strategy. They built Pluvicto (a prostate cancer radioligand) into a blockbuster by owning the platform, then expanding across targets and indications. The plan for NMTi payloads appears similar: prove the concept with lead programs targeting B7-H3 and HER2, then roll the payload technology across as many antibodies and tumor types as possible.
If the clinical data deliver, Novartis will own a proprietary payload family that competitors can't easily replicate. That's a sustainable competitive advantage in a space where most players are working with the same handful of warhead chemistries. If the data disappoint, this becomes a very expensive science experiment.
The deal is expected to close in the second half of 2026. Novartis plans to push Myricx's lead ADC programs toward Phase 1 clinical trials, where we'll finally learn whether NMTi payloads work as well in humans as they do in mice.
For a billion dollars upfront, Novartis is betting they will. The rest of the industry is watching closely, because the answer won't just determine whether this deal was smart. It could reshape what every ADC looks like a decade from now.
Deals & M&A5 min read
Genentech Cut 103 Jobs and Wrote a $490M Check on the Same Day
Genentech axed 103 scientists from its storied research unit and signed a $490 million breast cancer deal with Astex on virtually the same timeline. It's the clearest signal yet of how big pharma is reshuffling the R&D deck in 2026.
